PTK2 and neoplasm: As shown in Figure 6A,B, FAK inhibitor treatment promoted tumor cell sensitivity to chemotherapeutic agents such as paclitaxel and oxaliplatin in a dose‐dependent manner, and to a lesser extent, irinotecan.